Lupin shares in focus after exclusive deal with Chinese firm for diabetes, obesity management drug

December 30, 2025
Uncategorized

The drug is a fortnightly, or once-in-two weeks, injectable GLP-1. It is indicated for Type 2 diabetes and weight management, Lupin stated in its exchange filing.

Lupin shares in focus after exclusive deal with Chinese firm for diabetes, obesity management drug

Leave a ReplyCancel Reply

Stock to watch on February 16: IRB Infra, Torrent Pharma, Ola Electric, NBCC and more

Trade Setup for February 16: Nifty breaches key moving averages; downside risk toward 25,000 looms

Margin ͏trading made safer͏:͏ Understanding HDFC SKY’s 4x leverage model

SEBI looks to curb volatility in Gold and Silver ETFs, proposes to review price band

Manappuram Finance gets RBI’s conditional nod for proposed stake sale to Bain Capital